The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

Advanced hepatocellular carcinoma (HCC) is a formidable public health problem with limited curable treatment options. Axitinib, an oral tyrosine kinase inhibitor, is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. This anti-angio...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Hao, Liao, Jian, Wang, Liezhi, Jin, Chong, Mo, Jinggang, Xiang, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264605/
https://www.ncbi.nlm.nih.gov/pubmed/37325670
http://dx.doi.org/10.3389/fimmu.2023.1163967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264605/
https://www.ncbi.nlm.nih.gov/pubmed/37325670
http://dx.doi.org/10.3389/fimmu.2023.1163967

Ejemplares similares